A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

Status

Terminated

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04035434

Enrollment

Registered

2019-07-29

Start date

2019-07-22

Completion date

2024-10-04

Last updated

2025-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult B Cell ALL, B-cell Lymphoma, B-cell Malignancy, Non-Hodgkin Lymphoma

Keywords

CAR T, Non-Hodgkin Lymphoma, NHL, Lymphoma, Allogeneic, Leukemia

Brief summary

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX110 in subjects with relapsed or refractory B-cell malignancies.

Detailed description

The study may enroll up to 227 subjects in total. CTX110 is a CD19-directed chimeric antigen receptor (CAR) T cell immunotherapy comprised of allogeneic T cells prepared for the treatment of B cell malignancies. The cells are from healthy adult volunteer donors that are genetically modified ex vivo using CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats/ CRISPR-associated protein 9) gene editing components (single guide RNA and Cas9 nuclease).

Interventions

BIOLOGICALCTX110

CTX110 (CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components

Study design

Allocation

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Key Inclusion Criteria: 1. For NHL patients: Age ≥18 years. For B cell ALL patients: age ≥18 years to ≤70 years 2. Refractory or relapsed non-Hodgkin lymphoma, as evidenced by 2 or more lines of prior therapy, or histologically confirmed B cell ALL, refractory or relapsed. 3. Eastern Cooperative Oncology Group performance status 0 or 1. 4. Adequate renal, liver, cardiac and pulmonary organ function 5. Female subjects of childbearing potential and male subjects must agree to use acceptable method(s) of contraception from enrollment through at least 12 months after CTX110 infusion. Key

Exclusion criteria

1. For NHL patients: prior allogeneic HSCT. For B cell ALL patients: prior allogeneic HSCT within 6 months, and/or any evidence of GvHD. 2. History of central nervous system (CNS) involvement by malignancy 3. History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement. 4. Presence of bacterial, viral, or fungal infection that is uncontrolled. 5. Positive for HIV, or active hepatitis B virus or hepatitis C virus infection. 6. Previous or concurrent malignancy, except basal cell or squamous cell skin carcinoma, adequately resected and in situ carcinoma of cervix, or a previous malignancy that was completely resected and has been in remission for ≥5 years. 7. For NHL patients: Use of systemic anti-tumor therapy or investigational agent within 14 days or 5 half-lives, whichever is longer, of CTX110 infusion. For B cell ALL patients: Use of systemic antitumor therapy within 7 days of CTX110 infusion. 8. Primary immunodeficiency disorder or active autoimmune disease requiring steroids and/or other immunosuppressive therapy. 9. Women who are pregnant or breastfeeding.

Design outcomes

Primary

Measure	Time frame	Description
Dose Escalation Phase 1: Number of Participants With Dose-limiting Toxicities (DLT) in NHL and B Cell ALL Population	Up to 28 days	A DLT is defined as any of the following events occurring during the DLT evaluation period that persisted beyond the specified duration from onset: Grade ≥2 graft-versus-host disease (GvHD) that was steroid-refractory (e.g., progressive disease after 3 days of steroid treatment \[e.g., 1 mg/kg/day\], stable disease after 7 days, or partial response after 14 days of treatment); death during the DLT period, unless due to disease progression; Grade 4 neurotoxicity of any duration that was related or possibly related to CTX110; or any CTX110-related grade 3 or 4 toxicity deemed clinically significant by the investigator that did not improve within 72 hours.
Dose Expansion Phase 1 and Phase 2: Percentage of Participants With Objective Response Rate in NHL Population	Up to 5 years	The objective response rate (complete response + partial response) was analyzed as per Lugano Response Criteria for Malignant Lymphoma, as determined by independent central radiology review. For participants who received the second course of treatment, the response assessments before and after the second course are combined for the derivation of objective response. Percentages are calculated with the number of participants in the specific analysis set in each column as the denominator. Confidence intervals (CI) of percentage are calculated with Clopper-Pearson exact method.

Secondary

Measure	Time frame	Description
Dose Escalation and Expansion Phase 1: Progression Free Survival (PFS) in NHL Population	Up to 5 years	Progression-free survival (PFS) and event-free survival were calculated as the difference between date of CTX110 infusion and date of disease progression or death due to any cause. The median of PFS was calculated with the Kaplan-Meier method. The CIs of median PFS were calculated with the Brookmeyer and Crowley method with log-log transformation.
Dose Escalation and Expansion Phase 1: Median Overall Survival (OS) in NHL Population	Up to 5 years	Overall survival was calculated as the time between date of first dose of CTX110 and death due to any cause. Participants who are alive at the data cutoff date will be censored at their last date known to be alive. Median overall survival was calculated with the Kaplan-Meier method. CIs of median overall survival were calculated with the Brookmeyer and Crowley method with log-log transformation.
Dose Escalation and Expansion: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in NHL and B Cell ALL Population	Up to 5 years	A TEAE was any untoward medical occurrence or worsening of a pre-existing condition in a clinical trial participant who received the investigational medicinal product, regardless of a causal relationship with the treatment. An AE had to be classified as a serious adverse event (SAE) if it resulted in death, was life-threatening, required or prolonged hospitalization, caused persistent or significant disability or incapacity, led to a congenital anomaly or birth defect in a newborn, or was deemed a significant medical event by the investigator based on medical judgment.
Dose Escalation Phase 1: Percentage of Participants With Objective Response Rate in B Cell ALL Population	Up to 5 years	The objective response rate (complete response + complete remission with incomplete blood count recovery) was analyzed as per response criteria adapted from the National Comprehensive Cancer Network guidelines for treatment of acute lymphoblastic leukemia Version 2.2021, as determined by independent central radiology review. For -participants who receive the second course of treatment, the response assessments before and after the second course are combined for the derivation of objective response. Percentages are calculated with the number of participants in the specific analysis set in each column as the denominator. Confidence intervals (CI) of percentage are calculated with Clopper-Pearson exact method.
Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 1 pre-infusion, Day 1 post-infusion, Day 2, Day 3, Day 5, Day 8, Day 10, Day 14, Day 21, Day 28, Month 2, Month 3, Month 6, Month 9, Month 12 and Month 24	Blood samples were collected for the analysis of mean concentration of CTX110 in blood (copies per micrograms deoxyribose nucleic acid \[DNA\]) over time following the first CTX110 infusion. Cohort A DL4a and DL4b were combined, as the same dose was administered. Mean concentration values of CTX110 have been presented by dose level.
Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 1 pre-infusion, Day 1 post-infusion, Day 2, Day 3, Day 5, Day 8, Day 10, Day 14, Day 21, Day 28, and Month 2	Blood samples were collected for the analysis of mean concentration of CTX110 in blood (copies per micrograms deoxyribose nucleic acid \[DNA\]) over time following the first CTX110 infusion.
Dose Escalation and Expansion: Number of Participants With Serious Adverse Events (SAEs) in NHL and B Cell ALL Population	Up to 5 years	An AE had to be classified as a serious adverse event (SAE) if it resulted in death, was life-threatening, required or prolonged hospitalization, caused persistent or significant disability or incapacity, led to a congenital anomaly or birth defect in a newborn, or was deemed a significant medical event by the investigator based on medical judgment.
Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Up to 5 years	Blood samples were collected for the analysis of laboratory parameters including hematology, clinical chemistry and coagulation parameters. The hematology parameters included: Lymphocyte count decreased, Neutrophil count decreased, White blood cell decreased, Anemia, Platelet count decreased, leukocytosis and Lymphocyte count increased. Chemistry parameters included: Hypoalbuminemia, Aspartate aminotransferase increased, Alanine aminotransferase increased, Hypokalemia, Chronic kidney disease, Blood bilirubin increased, Creatinine increased, Hypermagnesemia, Hypernatremia, Hypercalcemia, Hyperkalemia, and Hypoglycemia. Coagulation parameters included: Activated partial thromboplastin time prolonged, Fibrinogen decreased, and INR increased. Grade 3 and above severity of laboratory abnormalities are considered as clinically significant laboratory abnormalities.
Dose Escalation and Expansion Phase 1: Duration of Response in NHL Population	Up to 5 years	Duration of response was only reported for the participants who showed objective response events. This was calculated as the time between first objective response and date of disease progression or death due to any cause. Median duration of response was calculated with the Kaplan-Meier method. Confidence intervals of median duration of response were calculated with the Brookmeyer and Crowley method with log-log transformation.

Countries

Australia, Canada, France, Germany, Spain, United States

Participant flow

Recruitment details

The study comprises 4 cohorts: Cohorts A, B, and C enrolled adult participants with non-Hodgkin lymphoma (NHL); Cohort D enrolled participants with adult B cell acute lymphoblastic leukemia (ALL). A total of 93 participants were enrolled; 3 participants died prior to receiving CTX110 (1 due to pulmonary haemorrhage that occurred after lymphodepleting \[LD\] chemotherapy but was assessed as not related to LD chemotherapy, and 2 due to disease progression).

Pre-assignment details

The study was designed to be divided into 2 phases. A total of 8 participants were enrolled in the Phase 2 dose expansion. Due to a high proportion of non-quantifiable values, the secondary efficacy endpoints for Phase 2 participants could not be calculated. The study was terminated early in Phase 2 at the sponsor's discretion.

Participants by arm

Arm	Count
Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells) Participants with non-Hodgkin lymphoma (NHL) received lymphodepleting (LD) chemotherapy consisting of fludarabine (30 mg/m²) and cyclophosphamide (500 mg/m²) administered intravenously (IV) once daily for three consecutive days. LD chemotherapy was completed at least 48 hours, but no more than 7 days, before infusion of CTX110. CTX110 was given as a single IV infusion of 3x10\^7 CAR+ T cells.	3
Cohort A: DL 2 (1x10^8 CAR+ T Cells) Participants with NHL received LD chemotherapy consisting of fludarabine (30 mg/m²) and cyclophosphamide (500 mg/m²) administered IV once daily for three consecutive days. LD chemotherapy was completed at least 48 hours, but no more than 7 days, before infusion of CTX110. CTX110 was given as a single IV infusion of 1x10\^8 CAR+ T cells.	3
Cohort A: DL 3 (3x10^8 CAR+ T Cells) Participants with NHL received LD chemotherapy consisting of fludarabine (30 mg/m²) and cyclophosphamide (500 mg/m²) administered IV once daily for three consecutive days. LD chemotherapy was completed at least 48 hours, but no more than 7 days, before infusion of CTX110. CTX110 was given as a single IV infusion of 3×10\^8 CAR+ T cells.	6
Cohort A: DL 3b (4.5x10^8 CAR+ T Cells) Participants with NHL received LD chemotherapy consisting of fludarabine (30 mg/m²) and cyclophosphamide (500 mg/m²) administered IV once daily for three consecutive days. LD chemotherapy was completed at least 48 hours, but no more than 7 days, before infusion of CTX110. CTX110 was given as a single IV infusion of 4.5×10\^8 CAR+ T cells.	6
Cohort A: DL 4a (6x10^8 CAR+ T Cells) Participants with NHL received LD chemotherapy consisting of fludarabine (30 mg/m²) and cyclophosphamide (500 mg/m²) administered IV once daily for three consecutive days. LD chemotherapy was completed at least 48 hours, but no more than 7 days, before infusion of CTX110. CTX110 was given as a single IV infusion of 6×10\^8 CAR+ T cells.	10
Cohort A: DL 4b (6x10^8 CAR+ T Cells) Participants with NHL received LD chemotherapy consisting of fludarabine (30 mg/m²) and cyclophosphamide (500 mg/m²) administered IV once daily for three consecutive days. LD chemotherapy was completed at least 48 hours, but no more than 7 days, before infusion of CTX110. CTX110 was given as a single IV infusion of 6×10\^8 CAR+ T cells and includes participants with 2 planned infusions during treatment course 1.	35
Cohort B: DL 4 (6x10^8 CAR+ T Cells) Participants with NHL received LD chemotherapy consisting of fludarabine (30 mg/m²) and cyclophosphamide (750 mg/m²) administered IV once daily for three consecutive days. LD chemotherapy was completed at least 48 hours, but no more than 7 days, before infusion of CTX110. CTX110 was given as a single IV infusion of 6×10\^8 CAR+ T cells.	1
Cohort C: DL 3 (3x10^8 CAR+ T Cells) Participants with NHL received daratumumab (16 mg/kg) at least 1 day before LD chemotherapy and within 10 days prior to CTX110 infusion. LD chemotherapy (fludarabine 30 mg/m² and cyclophosphamide 500 mg/m² IV daily for 3 days) was completed 48 hours to 7 days before CTX110 infusion. Participants with stable disease or better on Day 28 received additional daratumumab doses at Day 28 (±4 days) and Month 2 (±4 days). CTX110 was given as a single IV infusion of 3x10\^8 CAR+ T cells.	5
Cohort C: DL 4 (6x10^8 CAR+ T Cells) Participants with NHL received daratumumab (16 mg/kg) at least 1 day before LD chemotherapy and within 10 days prior to CTX110 infusion. LD chemotherapy (fludarabine 30 mg/m² and cyclophosphamide 500 mg/m² IV daily for 3 days) was completed 48 hours to 7 days before CTX110 infusion. Participants with stable disease or better on Day 28 received additional daratumumab doses at Day 28 (±4 days) and Month 2 (±4 days). CTX110 was given as a single IV infusion of 6×10\^8 CAR+ T cells.	5
B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells) Participants with B Cell ALL received LD chemotherapy consisting of fludarabine (30 mg/m²) and cyclophosphamide (500 mg/m²) administered IV once daily for three consecutive days. LD chemotherapy was completed at least 48 hours, but no more than 7 days, before infusion of CTX110. CTX110 was given as a single IV infusion of 1x10\^8 CAR+ T cells.	4
B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells) Participants with B Cell ALL received LD chemotherapy consisting of fludarabine (30 mg/m²) and cyclophosphamide (500 mg/m²) administered IV once daily for three consecutive days. LD chemotherapy was completed at least 48 hours, but no more than 7 days, before infusion of CTX110. CTX110 was given as a single IV infusion of 3×10\^8 CAR+ T cells.	5
B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells) Participants with B Cell ALL received daratumumab (16 mg/kg) at least 1 day before LD chemotherapy and within 10 days prior to CTX110 infusion. LD chemotherapy (fludarabine 30 mg/m² and cyclophosphamide 500 mg/m² IV daily for 3 days) was completed 48 hours to 7 days before CTX110 infusion. Participants with stable disease or better on Day 28 received additional daratumumab doses at Day 28 (±4 days) and Month 2 (±4 days). CTX110 was given as a single IV infusion of 6×10\^8 CAR+ T cells.	7
Total	90

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003	FG004	FG005	FG006	FG007	FG008	FG009	FG010	FG011	FG012
Dose Escalation Phase (Up to 5 Years)	Death	3	1	4	3	8	3	0	1	3	4	3	2	1
Dose Escalation Phase (Up to 5 Years)	Lost to Follow-up	0	0	0	1	0	0	0	0	0	0	0	0	0
Dose Escalation Phase (Up to 5 Years)	Study terminated by the Sponsor	0	1	2	0	1	1	0	0	2	1	0	2	6
Dose Escalation Phase (Up to 5 Years)	Withdrawal by Subject	0	1	0	2	1	0	0	0	0	0	1	1	0
Dose Expansion Phase (Up to 5 Years)	Death	0	0	0	0	0	14	3	0	0	0	0	0	0
Dose Expansion Phase (Up to 5 Years)	Study terminated by the Sponsor	0	0	0	0	0	8	4	0	0	0	0	0	0
Dose Expansion Phase (Up to 5 Years)	Withdrawal by Subject	0	0	0	0	0	1	1	0	0	0	0	0	0

Baseline characteristics

Characteristic	Total	B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)
Age, Continuous	60.0 Years STANDARD_DEVIATION 14.5	47.7 Years STANDARD_DEVIATION 17.61	39.4 Years STANDARD_DEVIATION 13.83	35.0 Years STANDARD_DEVIATION 10.3	63.8 Years STANDARD_DEVIATION 6.65	71.0 Years STANDARD_DEVIATION 8.43	59.0 Years	64.0 Years STANDARD_DEVIATION 11.74	61.8 Years STANDARD_DEVIATION 10.9	61.5 Years STANDARD_DEVIATION 18.29	68.2 Years STANDARD_DEVIATION 5.34	65.3 Years STANDARD_DEVIATION 8.08	54.3 Years STANDARD_DEVIATION 5.86
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Asian	5 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	2 Participants	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants
Race (NIH/OMB) Black or African American	4 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	6 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	2 Participants	2 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) White	75 Participants	6 Participants	4 Participants	4 Participants	4 Participants	5 Participants	1 Participants	30 Participants	7 Participants	4 Participants	6 Participants	2 Participants	2 Participants
Sex: Female, Male Female	29 Participants	3 Participants	2 Participants	1 Participants	2 Participants	2 Participants	0 Participants	9 Participants	2 Participants	2 Participants	4 Participants	1 Participants	1 Participants
Sex: Female, Male Male	61 Participants	4 Participants	3 Participants	3 Participants	3 Participants	3 Participants	1 Participants	26 Participants	8 Participants	4 Participants	2 Participants	2 Participants	2 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk	EG006 affected / at risk	EG007 affected / at risk	EG008 affected / at risk	EG009 affected / at risk	EG010 affected / at risk	EG011 affected / at risk
deaths Total, all-cause mortality	3 / 3	2 / 3	4 / 11	3 / 6	9 / 10	21 / 35	1 / 1	3 / 5	4 / 5	4 / 4	2 / 5	1 / 7
other Total, other adverse events	3 / 3	3 / 3	6 / 6	6 / 6	10 / 10	34 / 35	1 / 1	5 / 5	5 / 5	4 / 4	5 / 5	7 / 7
serious Total, serious adverse events	3 / 3	2 / 3	1 / 6	1 / 6	5 / 10	8 / 35	0 / 1	1 / 5	4 / 5	3 / 4	3 / 5	1 / 7

Outcome results

Primary

Dose Escalation Phase 1: Number of Participants With Dose-limiting Toxicities (DLT) in NHL and B Cell ALL Population

A DLT is defined as any of the following events occurring during the DLT evaluation period that persisted beyond the specified duration from onset: Grade ≥2 graft-versus-host disease (GvHD) that was steroid-refractory (e.g., progressive disease after 3 days of steroid treatment \[e.g., 1 mg/kg/day\], stable disease after 7 days, or partial response after 14 days of treatment); death during the DLT period, unless due to disease progression; Grade 4 neurotoxicity of any duration that was related or possibly related to CTX110; or any CTX110-related grade 3 or 4 toxicity deemed clinically significant by the investigator that did not improve within 72 hours.

Time frame: Up to 28 days

Population: DLT Evaluable Set comprised of participants who received CTX110 and are followed for at least 28 days post-infusion or withdraw consent after experiencing a DLT.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation Phase 1: Number of Participants With Dose-limiting Toxicities (DLT) in NHL and B Cell ALL Population	0 Participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation Phase 1: Number of Participants With Dose-limiting Toxicities (DLT) in NHL and B Cell ALL Population	0 Participants
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation Phase 1: Number of Participants With Dose-limiting Toxicities (DLT) in NHL and B Cell ALL Population	0 Participants
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation Phase 1: Number of Participants With Dose-limiting Toxicities (DLT) in NHL and B Cell ALL Population	0 Participants
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation Phase 1: Number of Participants With Dose-limiting Toxicities (DLT) in NHL and B Cell ALL Population	1 Participants
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation Phase 1: Number of Participants With Dose-limiting Toxicities (DLT) in NHL and B Cell ALL Population	0 Participants
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation Phase 1: Number of Participants With Dose-limiting Toxicities (DLT) in NHL and B Cell ALL Population	0 Participants
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation Phase 1: Number of Participants With Dose-limiting Toxicities (DLT) in NHL and B Cell ALL Population	0 Participants
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation Phase 1: Number of Participants With Dose-limiting Toxicities (DLT) in NHL and B Cell ALL Population	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation Phase 1: Number of Participants With Dose-limiting Toxicities (DLT) in NHL and B Cell ALL Population	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation Phase 1: Number of Participants With Dose-limiting Toxicities (DLT) in NHL and B Cell ALL Population	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation Phase 1: Number of Participants With Dose-limiting Toxicities (DLT) in NHL and B Cell ALL Population	0 Participants

Primary

Dose Expansion Phase 1 and Phase 2: Percentage of Participants With Objective Response Rate in NHL Population

The objective response rate (complete response + partial response) was analyzed as per Lugano Response Criteria for Malignant Lymphoma, as determined by independent central radiology review. For participants who received the second course of treatment, the response assessments before and after the second course are combined for the derivation of objective response. Percentages are calculated with the number of participants in the specific analysis set in each column as the denominator. Confidence intervals (CI) of percentage are calculated with Clopper-Pearson exact method.

Time frame: Up to 5 years

Population: Full Analysis Set comprised of participants who received CTX110 infusion have baseline and at least 1 post-baseline disease assessment.

Arm	Measure	Value (NUMBER)
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Expansion Phase 1 and Phase 2: Percentage of Participants With Objective Response Rate in NHL Population	60.9 Percentage of participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Expansion Phase 1 and Phase 2: Percentage of Participants With Objective Response Rate in NHL Population	75.0 Percentage of participants

Secondary

Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population

Blood samples were collected for the analysis of mean concentration of CTX110 in blood (copies per micrograms deoxyribose nucleic acid \[DNA\]) over time following the first CTX110 infusion. Cohort A DL4a and DL4b were combined, as the same dose was administered. Mean concentration values of CTX110 have been presented by dose level.

Time frame: Day 1 pre-infusion, Day 1 post-infusion, Day 2, Day 3, Day 5, Day 8, Day 10, Day 14, Day 21, Day 28, Month 2, Month 3, Month 6, Month 9, Month 12 and Month 24

Population: Full Analysis Set. Only those participants with data available at specified timepoints has been presented.

Arm	Measure	Group	Value (MEAN)	Dispersion
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Month 6	2.90 Copies per micrograms DNA	Standard Deviation 0
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Month 2	3.88 Copies per micrograms DNA	Standard Deviation 1.379
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 3	8.36 Copies per micrograms DNA	Standard Deviation 5.31
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 8	3763.68 Copies per micrograms DNA	Standard Deviation 8138.642
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 1 pre-infusion	2.90 Copies per micrograms DNA	Standard Deviation 0
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 2	7.27 Copies per micrograms DNA	Standard Deviation 6.403
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 28	4.00 Copies per micrograms DNA	Standard Deviation 2.452
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 10	180.87 Copies per micrograms DNA	Standard Deviation 209.131
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 5	25.47 Copies per micrograms DNA	Standard Deviation 21.898
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 1 post-infusion	144.95 Copies per micrograms DNA	Standard Deviation 147.856
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Month 3	3.55 Copies per micrograms DNA	Standard Deviation 1.126
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 21	2.90 Copies per micrograms DNA	Standard Deviation 0
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 14	2.90 Copies per micrograms DNA	Standard Deviation 0
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 21	2.90 Copies per micrograms DNA	Standard Deviation 0
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 5	220.78 Copies per micrograms DNA	Standard Deviation 246.411
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Month 12	2.90 Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 14	3.55 Copies per micrograms DNA	Standard Deviation 1.592
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 8	4337.42 Copies per micrograms DNA	Standard Deviation 7721.088
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Month 9	2.90 Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 10	452.03 Copies per micrograms DNA	Standard Deviation 941.853
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 1 post-infusion	829.37 Copies per micrograms DNA	Standard Deviation 1552.483
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 1 pre-infusion	3.55 Copies per micrograms DNA	Standard Deviation 1.592
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Month 6	2.90 Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Month 3	2.90 Copies per micrograms DNA	Standard Deviation 0
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 2	10.77 Copies per micrograms DNA	Standard Deviation 13.999
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Month 24	2.90 Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Month 2	2.90 Copies per micrograms DNA	Standard Deviation 0
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 3	12.46 Copies per micrograms DNA	Standard Deviation 9.656
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 28	2.90 Copies per micrograms DNA	Standard Deviation 0
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 3	22.03 Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 1 pre-infusion	2.90 Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 1 post-infusion	472.20 Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 2	28.57 Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 5	311.67 Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 8	13269.43 Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 10	25719.13 Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 14	9.93 Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 21	2.90 Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 28	2.90 Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Month 2	NA Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Month 3	NA Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Month 6	NA Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Month 9	NA Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Month 12	NA Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Month 24	NA Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 1 pre-infusion	2.90 Copies per micrograms DNA	Standard Deviation 0
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 1 post-infusion	105.22 Copies per micrograms DNA	Standard Deviation 23.028
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 21	64.48 Copies per micrograms DNA	Standard Deviation 123.167
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Month 12	2.90 Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Month 2	11.17 Copies per micrograms DNA	Standard Deviation 14.318
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 5	80.40 Copies per micrograms DNA	Standard Deviation 33.878
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Month 3	2.90 Copies per micrograms DNA	Standard Deviation 0
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 2	35.62 Copies per micrograms DNA	Standard Deviation 22.359
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 8	5844.98 Copies per micrograms DNA	Standard Deviation 9600.631
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 10	19018.53 Copies per micrograms DNA	Standard Deviation 42303.294
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 3	16.76 Copies per micrograms DNA	Standard Deviation 13.05
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Month 24	NA Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 28	6.67 Copies per micrograms DNA	Standard Deviation 8.437
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 14	2435.23 Copies per micrograms DNA	Standard Deviation 5423.525
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Month 24	NA Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 14	51.73 Copies per micrograms DNA	Standard Deviation 87.882
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 1 pre-infusion	2.90 Copies per micrograms DNA	Standard Deviation 0
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 21	3.88 Copies per micrograms DNA	Standard Deviation 1.95
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 3	204.43 Copies per micrograms DNA	Standard Deviation 300.219
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 28	2.90 Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 2	72.39 Copies per micrograms DNA	Standard Deviation 107.323
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Month 2	2.90 Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Month 12	2.90 Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Month 3	2.90 Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 1 post-infusion	636.29 Copies per micrograms DNA	Standard Deviation 352.7
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 8	719.13 Copies per micrograms DNA	Standard Deviation 231.318
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 10	297.91 Copies per micrograms DNA	Standard Deviation 248.623
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 5	487.13 Copies per micrograms DNA	Standard Deviation 262.303
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 2	42.39 Copies per micrograms DNA	Standard Deviation 101.461
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 28	8.32 Copies per micrograms DNA	Standard Deviation 28.058
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 8	10277.87 Copies per micrograms DNA	Standard Deviation 27526.126
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 5	770.14 Copies per micrograms DNA	Standard Deviation 3312.713
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 21	2537.64 Copies per micrograms DNA	Standard Deviation 11074.754
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 1 pre-infusion	3.08 Copies per micrograms DNA	Standard Deviation 0.934
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 1 post-infusion	979.25 Copies per micrograms DNA	Standard Deviation 1658.499
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 3	35.80 Copies per micrograms DNA	Standard Deviation 98.739
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Month 2	2.90 Copies per micrograms DNA	Standard Deviation 0
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 14	2186.81 Copies per micrograms DNA	Standard Deviation 13766.282
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Month 3	2.90 Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population	Day 10	4056.03 Copies per micrograms DNA	Standard Deviation 19737.607

Secondary

Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population

Blood samples were collected for the analysis of laboratory parameters including hematology, clinical chemistry and coagulation parameters. The hematology parameters included: Lymphocyte count decreased, Neutrophil count decreased, White blood cell decreased, Anemia, Platelet count decreased, leukocytosis and Lymphocyte count increased. Chemistry parameters included: Hypoalbuminemia, Aspartate aminotransferase increased, Alanine aminotransferase increased, Hypokalemia, Chronic kidney disease, Blood bilirubin increased, Creatinine increased, Hypermagnesemia, Hypernatremia, Hypercalcemia, Hyperkalemia, and Hypoglycemia. Coagulation parameters included: Activated partial thromboplastin time prolonged, Fibrinogen decreased, and INR increased. Grade 3 and above severity of laboratory abnormalities are considered as clinically significant laboratory abnormalities.

Time frame: Up to 5 years

Population: Safety Analysis Set. The safety data are presented by treatment received and not by study phase.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Platelet count decreased	1 Participants
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Activated partial thromboplastin time prolonged	0 Participants
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	White blood cell decreased	3 Participants
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypermagnesemia	0 Participants
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Anemia	1 Participants
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Fibrinogen decreased	0 Participants
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Alanine aminotransferase increased	0 Participants
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypoglycemia	0 Participants
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Aspartate aminotransferase increased	0 Participants
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hyperkalemia	0 Participants
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypercalcemia	1 Participants
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Chronic kidney disease	0 Participants
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Neutrophil count decreased	3 Participants
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Leukocytosis	0 Participants
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypoalbuminemia	0 Participants
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Blood bilirubin increased	0 Participants
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Creatinine increased	0 Participants
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Lymphocyte count increased	0 Participants
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Lymphocyte count decreased	3 Participants
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypernatremia	0 Participants
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypokalemia	1 Participants
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	INR increased	0 Participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypokalemia	1 Participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypermagnesemia	0 Participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypercalcemia	1 Participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Neutrophil count decreased	3 Participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	INR increased	0 Participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	White blood cell decreased	2 Participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Fibrinogen decreased	0 Participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Anemia	1 Participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Activated partial thromboplastin time prolonged	0 Participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypernatremia	0 Participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Platelet count decreased	2 Participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Lymphocyte count decreased	3 Participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Creatinine increased	0 Participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Lymphocyte count increased	0 Participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Blood bilirubin increased	0 Participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypoalbuminemia	1 Participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Chronic kidney disease	0 Participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Aspartate aminotransferase increased	1 Participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypoglycemia	0 Participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Alanine aminotransferase increased	1 Participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Leukocytosis	0 Participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hyperkalemia	0 Participants
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Aspartate aminotransferase increased	0 Participants
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypercalcemia	0 Participants
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	White blood cell decreased	6 Participants
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Blood bilirubin increased	0 Participants
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hyperkalemia	0 Participants
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypermagnesemia	0 Participants
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Neutrophil count decreased	6 Participants
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypokalemia	0 Participants
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypoalbuminemia	1 Participants
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	INR increased	0 Participants
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Chronic kidney disease	0 Participants
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Anemia	4 Participants
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Activated partial thromboplastin time prolonged	0 Participants
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Alanine aminotransferase increased	0 Participants
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Creatinine increased	0 Participants
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Fibrinogen decreased	0 Participants
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Lymphocyte count decreased	6 Participants
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Platelet count decreased	3 Participants
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Lymphocyte count increased	0 Participants
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypernatremia	0 Participants
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypoglycemia	0 Participants
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Leukocytosis	0 Participants
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Fibrinogen decreased	0 Participants
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypernatremia	0 Participants
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Platelet count decreased	4 Participants
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Alanine aminotransferase increased	0 Participants
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	INR increased	0 Participants
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Creatinine increased	0 Participants
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypokalemia	0 Participants
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Lymphocyte count increased	0 Participants
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Blood bilirubin increased	0 Participants
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Neutrophil count decreased	6 Participants
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypoalbuminemia	0 Participants
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Leukocytosis	0 Participants
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Chronic kidney disease	0 Participants
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Aspartate aminotransferase increased	1 Participants
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypoglycemia	0 Participants
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypermagnesemia	0 Participants
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypercalcemia	0 Participants
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Lymphocyte count decreased	6 Participants
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	White blood cell decreased	6 Participants
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Activated partial thromboplastin time prolonged	0 Participants
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hyperkalemia	0 Participants
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Anemia	3 Participants
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Aspartate aminotransferase increased	0 Participants
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Leukocytosis	0 Participants
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Platelet count decreased	6 Participants
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Lymphocyte count increased	0 Participants
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypercalcemia	0 Participants
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Fibrinogen decreased	0 Participants
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	White blood cell decreased	10 Participants
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypernatremia	1 Participants
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Alanine aminotransferase increased	0 Participants
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hyperkalemia	0 Participants
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Anemia	8 Participants
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Activated partial thromboplastin time prolonged	0 Participants
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Chronic kidney disease	1 Participants
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Lymphocyte count decreased	10 Participants
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypoalbuminemia	0 Participants
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypokalemia	1 Participants
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	INR increased	0 Participants
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypoglycemia	0 Participants
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Blood bilirubin increased	0 Participants
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypermagnesemia	1 Participants
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Neutrophil count decreased	10 Participants
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Creatinine increased	1 Participants
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Creatinine increased	0 Participants
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Lymphocyte count decreased	35 Participants
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Neutrophil count decreased	35 Participants
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	White blood cell decreased	35 Participants
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Anemia	17 Participants
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Platelet count decreased	19 Participants
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Lymphocyte count increased	0 Participants
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypoalbuminemia	0 Participants
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Aspartate aminotransferase increased	0 Participants
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Alanine aminotransferase increased	3 Participants
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypokalemia	2 Participants
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypercalcemia	0 Participants
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypermagnesemia	1 Participants
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hyperkalemia	0 Participants
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypoglycemia	0 Participants
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Chronic kidney disease	1 Participants
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Blood bilirubin increased	1 Participants
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypernatremia	0 Participants
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Activated partial thromboplastin time prolonged	4 Participants
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Fibrinogen decreased	0 Participants
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	INR increased	0 Participants
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Leukocytosis	0 Participants
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Alanine aminotransferase increased	0 Participants
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	White blood cell decreased	1 Participants
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Platelet count decreased	1 Participants
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Leukocytosis	0 Participants
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Blood bilirubin increased	0 Participants
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hyperkalemia	0 Participants
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Creatinine increased	0 Participants
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Activated partial thromboplastin time prolonged	0 Participants
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Lymphocyte count increased	0 Participants
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Anemia	0 Participants
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	INR increased	0 Participants
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Neutrophil count decreased	1 Participants
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypokalemia	0 Participants
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypernatremia	0 Participants
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Aspartate aminotransferase increased	0 Participants
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Lymphocyte count decreased	1 Participants
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypoglycemia	0 Participants
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypercalcemia	0 Participants
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypermagnesemia	0 Participants
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypoalbuminemia	0 Participants
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Fibrinogen decreased	0 Participants
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Chronic kidney disease	0 Participants
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypoalbuminemia	0 Participants
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypermagnesemia	1 Participants
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Anemia	2 Participants
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	White blood cell decreased	5 Participants
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Leukocytosis	0 Participants
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	INR increased	0 Participants
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypokalemia	0 Participants
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Lymphocyte count decreased	5 Participants
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Lymphocyte count increased	0 Participants
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Creatinine increased	0 Participants
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Aspartate aminotransferase increased	2 Participants
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Blood bilirubin increased	0 Participants
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Fibrinogen decreased	0 Participants
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Neutrophil count decreased	5 Participants
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Activated partial thromboplastin time prolonged	1 Participants
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Chronic kidney disease	0 Participants
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Alanine aminotransferase increased	2 Participants
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hyperkalemia	1 Participants
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypoglycemia	1 Participants
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypernatremia	0 Participants
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypercalcemia	0 Participants
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Platelet count decreased	2 Participants
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypermagnesemia	0 Participants
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Creatinine increased	0 Participants
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypernatremia	0 Participants
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypokalemia	0 Participants
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Anemia	3 Participants
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Alanine aminotransferase increased	0 Participants
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	INR increased	0 Participants
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hyperkalemia	0 Participants
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Aspartate aminotransferase increased	0 Participants
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypoglycemia	0 Participants
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Lymphocyte count decreased	5 Participants
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Neutrophil count decreased	5 Participants
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Fibrinogen decreased	0 Participants
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypoalbuminemia	1 Participants
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Chronic kidney disease	0 Participants
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	White blood cell decreased	5 Participants
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Activated partial thromboplastin time prolonged	1 Participants
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Lymphocyte count increased	0 Participants
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Blood bilirubin increased	0 Participants
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Leukocytosis	0 Participants
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypercalcemia	0 Participants
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Platelet count decreased	5 Participants
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Lymphocyte count increased	1 Participants
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Alanine aminotransferase increased	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypermagnesemia	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hyperkalemia	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Aspartate aminotransferase increased	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypoglycemia	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypoalbuminemia	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Chronic kidney disease	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Blood bilirubin increased	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Platelet count decreased	2 Participants
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Creatinine increased	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Anemia	2 Participants
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypernatremia	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	White blood cell decreased	4 Participants
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Activated partial thromboplastin time prolonged	1 Participants
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Leukocytosis	1 Participants
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Fibrinogen decreased	1 Participants
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Neutrophil count decreased	4 Participants
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	INR increased	1 Participants
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypokalemia	1 Participants
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Lymphocyte count decreased	4 Participants
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypercalcemia	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	White blood cell decreased	5 Participants
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Blood bilirubin increased	1 Participants
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Lymphocyte count increased	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Activated partial thromboplastin time prolonged	1 Participants
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Chronic kidney disease	1 Participants
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Neutrophil count decreased	5 Participants
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypercalcemia	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypoalbuminemia	1 Participants
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypermagnesemia	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Fibrinogen decreased	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Alanine aminotransferase increased	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypoglycemia	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Leukocytosis	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hyperkalemia	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Aspartate aminotransferase increased	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	INR increased	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Lymphocyte count decreased	5 Participants
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Anemia	3 Participants
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypokalemia	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypernatremia	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Creatinine increased	1 Participants
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Platelet count decreased	3 Participants
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypoalbuminemia	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Platelet count decreased	3 Participants
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Blood bilirubin increased	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hyperkalemia	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Lymphocyte count decreased	7 Participants
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypermagnesemia	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypernatremia	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Activated partial thromboplastin time prolonged	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Lymphocyte count increased	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Chronic kidney disease	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Anemia	3 Participants
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Neutrophil count decreased	7 Participants
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Creatinine increased	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Aspartate aminotransferase increased	1 Participants
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Leukocytosis	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Alanine aminotransferase increased	2 Participants
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypoglycemia	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	White blood cell decreased	7 Participants
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	INR increased	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Fibrinogen decreased	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypercalcemia	0 Participants
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population	Hypokalemia	0 Participants

Secondary

Dose Escalation and Expansion: Number of Participants With Serious Adverse Events (SAEs) in NHL and B Cell ALL Population

An AE had to be classified as a serious adverse event (SAE) if it resulted in death, was life-threatening, required or prolonged hospitalization, caused persistent or significant disability or incapacity, led to a congenital anomaly or birth defect in a newborn, or was deemed a significant medical event by the investigator based on medical judgment.

Time frame: Up to 5 years

Population: Safety Analysis Set. The safety data are presented by treatment received and not by study phase.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Serious Adverse Events (SAEs) in NHL and B Cell ALL Population	3 Participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Serious Adverse Events (SAEs) in NHL and B Cell ALL Population	2 Participants
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Serious Adverse Events (SAEs) in NHL and B Cell ALL Population	1 Participants
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Serious Adverse Events (SAEs) in NHL and B Cell ALL Population	1 Participants
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Serious Adverse Events (SAEs) in NHL and B Cell ALL Population	5 Participants
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Serious Adverse Events (SAEs) in NHL and B Cell ALL Population	8 Participants
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Serious Adverse Events (SAEs) in NHL and B Cell ALL Population	0 Participants
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Serious Adverse Events (SAEs) in NHL and B Cell ALL Population	1 Participants
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Serious Adverse Events (SAEs) in NHL and B Cell ALL Population	4 Participants
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Serious Adverse Events (SAEs) in NHL and B Cell ALL Population	3 Participants
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Serious Adverse Events (SAEs) in NHL and B Cell ALL Population	3 Participants
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Serious Adverse Events (SAEs) in NHL and B Cell ALL Population	1 Participants

Secondary

Dose Escalation and Expansion: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in NHL and B Cell ALL Population

A TEAE was any untoward medical occurrence or worsening of a pre-existing condition in a clinical trial participant who received the investigational medicinal product, regardless of a causal relationship with the treatment. An AE had to be classified as a serious adverse event (SAE) if it resulted in death, was life-threatening, required or prolonged hospitalization, caused persistent or significant disability or incapacity, led to a congenital anomaly or birth defect in a newborn, or was deemed a significant medical event by the investigator based on medical judgment.

Time frame: Up to 5 years

Population: Safety Analysis Set. The safety data are presented by treatment received and not by study phase.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in NHL and B Cell ALL Population	3 Participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in NHL and B Cell ALL Population	3 Participants
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in NHL and B Cell ALL Population	6 Participants
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in NHL and B Cell ALL Population	6 Participants
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in NHL and B Cell ALL Population	10 Participants
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in NHL and B Cell ALL Population	34 Participants
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in NHL and B Cell ALL Population	1 Participants
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in NHL and B Cell ALL Population	5 Participants
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in NHL and B Cell ALL Population	5 Participants
Phase 1: B Cell ALL: Cohort D: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in NHL and B Cell ALL Population	4 Participants
Phase 1: B Cell ALL: Cohort D: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in NHL and B Cell ALL Population	5 Participants
Phase 1: B Cell ALL: Cohort D: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in NHL and B Cell ALL Population	7 Participants

Secondary

Dose Escalation and Expansion Phase 1: Duration of Response in NHL Population

Duration of response was only reported for the participants who showed objective response events. This was calculated as the time between first objective response and date of disease progression or death due to any cause. Median duration of response was calculated with the Kaplan-Meier method. Confidence intervals of median duration of response were calculated with the Brookmeyer and Crowley method with log-log transformation.

Time frame: Up to 5 years

Population: Full Analysis Set: Participants who reported objective response events were analyzed. The duration of response for Phase 2 could not be calculated due to the high proportion of non-quantifiable values.

Arm	Measure	Value (MEDIAN)
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Duration of Response in NHL Population	9.20 Months
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Duration of Response in NHL Population	3.75 Months
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Duration of Response in NHL Population	3.52 Months
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Duration of Response in NHL Population	1.02 Months
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Duration of Response in NHL Population	3.60 Months
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Duration of Response in NHL Population	NA Months
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Duration of Response in NHL Population	2.20 Months
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Duration of Response in NHL Population	1.56 Months

Secondary

Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population

Blood samples were collected for the analysis of mean concentration of CTX110 in blood (copies per micrograms deoxyribose nucleic acid \[DNA\]) over time following the first CTX110 infusion.

Time frame: Day 1 pre-infusion, Day 1 post-infusion, Day 2, Day 3, Day 5, Day 8, Day 10, Day 14, Day 21, Day 28, and Month 2

Population: Full Analysis Set

Arm	Measure	Group	Value (MEAN)	Dispersion
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 14	1040.13 Copies per micrograms DNA	Standard Deviation 1466.869
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 5	28.65 Copies per micrograms DNA	Standard Deviation 36.011
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 28	2.90 Copies per micrograms DNA	Standard Deviation 0
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 10	226.32 Copies per micrograms DNA	Standard Deviation 290.508
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 8	71.30 Copies per micrograms DNA	Standard Deviation 118.215
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 1 pre-infusion	13.43 Copies per micrograms DNA	Standard Deviation 21.067
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 2	4.20 Copies per micrograms DNA	Standard Deviation 2.252
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 1 post-infusion	781.86 Copies per micrograms DNA	Standard Deviation 1395.907
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 21	3.55 Copies per micrograms DNA	Standard Deviation 1.126
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 3	13.46 Copies per micrograms DNA	Standard Deviation 14.905
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Month 2	2.90 Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 8	16846.17 Copies per micrograms DNA	Standard Deviation 33459.507
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 1 pre-infusion	3.29 Copies per micrograms DNA	Standard Deviation 0.872
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 1 post-infusion	1983.57 Copies per micrograms DNA	Standard Deviation 1677.746
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 2	93.47 Copies per micrograms DNA	Standard Deviation 149.22
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 3	20.47 Copies per micrograms DNA	Standard Deviation 25.356
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 5	42.37 Copies per micrograms DNA	Standard Deviation 47.444
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 10	26.17 Copies per micrograms DNA	Standard Deviation 41.517
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 14	2.90 Copies per micrograms DNA	Standard Deviation 0
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 21	2.90 Copies per micrograms DNA	Standard Deviation 0
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 28	2.90 Copies per micrograms DNA	Standard Deviation 0
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Month 2	2.90 Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 28	2.90 Copies per micrograms DNA	Standard Deviation 0
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 14	380.29 Copies per micrograms DNA	Standard Deviation 924.424
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 2	18.13 Copies per micrograms DNA	Standard Deviation 17.532
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 1 pre-infusion	2.90 Copies per micrograms DNA	Standard Deviation 0
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 21	2.90 Copies per micrograms DNA	Standard Deviation 0
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 1 post-infusion	602.75 Copies per micrograms DNA	Standard Deviation 521.357
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 8	15941.89 Copies per micrograms DNA	Standard Deviation 30200.959
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 5	62.85 Copies per micrograms DNA	Standard Deviation 124.743
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Month 2	2.90 Copies per micrograms DNA	—
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 10	14177.59 Copies per micrograms DNA	Standard Deviation 23256.089
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population	Day 3	7.95 Copies per micrograms DNA	Standard Deviation 4.705

Secondary

Dose Escalation and Expansion Phase 1: Median Overall Survival (OS) in NHL Population

Overall survival was calculated as the time between date of first dose of CTX110 and death due to any cause. Participants who are alive at the data cutoff date will be censored at their last date known to be alive. Median overall survival was calculated with the Kaplan-Meier method. CIs of median overall survival were calculated with the Brookmeyer and Crowley method with log-log transformation.

Time frame: Up to 5 years

Population: Full Analysis Set: Participants reporting overall survival rate were analyzed. The median overall survival for Phase 2 could not be calculated due to the high proportion of non-quantifiable values.

Arm	Measure	Value (MEDIAN)
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Median Overall Survival (OS) in NHL Population	5.03 Months
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Median Overall Survival (OS) in NHL Population	37.16 Months
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Median Overall Survival (OS) in NHL Population	7.77 Months
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Median Overall Survival (OS) in NHL Population	NA Months
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Median Overall Survival (OS) in NHL Population	5.16 Months
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Median Overall Survival (OS) in NHL Population	14.26 Months
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Median Overall Survival (OS) in NHL Population	12.12 Months
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Median Overall Survival (OS) in NHL Population	7.39 Months
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Median Overall Survival (OS) in NHL Population	7.62 Months

Secondary

Dose Escalation and Expansion Phase 1: Progression Free Survival (PFS) in NHL Population

Progression-free survival (PFS) and event-free survival were calculated as the difference between date of CTX110 infusion and date of disease progression or death due to any cause. The median of PFS was calculated with the Kaplan-Meier method. The CIs of median PFS were calculated with the Brookmeyer and Crowley method with log-log transformation.

Time frame: Up to 5 years

Population: Full Analysis Set: Participants who reported PFS events were analyzed. The progression free survival for Phase 2 could not be calculated due to the high proportion of non-quantifiable values.

Arm	Measure	Value (MEDIAN)
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Progression Free Survival (PFS) in NHL Population	0.92 Months
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Progression Free Survival (PFS) in NHL Population	1.91 Months
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Progression Free Survival (PFS) in NHL Population	2.43 Months
Phase 1: NHL: Cohort A: DL 3b (4.5x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Progression Free Survival (PFS) in NHL Population	1.54 Months
Phase 1: NHL: Cohort A: DL 4a (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Progression Free Survival (PFS) in NHL Population	1.77 Months
Phase 1: NHL: Cohort A: DL 4b (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Progression Free Survival (PFS) in NHL Population	2.83 Months
Phase 1: NHL: Cohort B: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Progression Free Survival (PFS) in NHL Population	NA Months
Phase 1: NHL: Cohort C: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Progression Free Survival (PFS) in NHL Population	2.92 Months
Phase 1: NHL: Cohort C: DL 4 (6x10^8 CAR+ T Cells)	Dose Escalation and Expansion Phase 1: Progression Free Survival (PFS) in NHL Population	1.94 Months

Secondary

Dose Escalation Phase 1: Percentage of Participants With Objective Response Rate in B Cell ALL Population

The objective response rate (complete response + complete remission with incomplete blood count recovery) was analyzed as per response criteria adapted from the National Comprehensive Cancer Network guidelines for treatment of acute lymphoblastic leukemia Version 2.2021, as determined by independent central radiology review. For -participants who receive the second course of treatment, the response assessments before and after the second course are combined for the derivation of objective response. Percentages are calculated with the number of participants in the specific analysis set in each column as the denominator. Confidence intervals (CI) of percentage are calculated with Clopper-Pearson exact method.

Time frame: Up to 5 years

Population: Full Analysis Set comprised of participants who received CTX110 infusion have baseline and at least 1 post-baseline disease assessment.

Arm	Measure	Value (NUMBER)
Phase 1: NHL: Cohort A Dose Level (DL) 1 (3×10^7 CAR+ T Cells)	Dose Escalation Phase 1: Percentage of Participants With Objective Response Rate in B Cell ALL Population	25.0 Percentage of Participants
Phase 1: NHL: Cohort A: DL 2 (1x10^8 CAR+ T Cells)	Dose Escalation Phase 1: Percentage of Participants With Objective Response Rate in B Cell ALL Population	40.0 Percentage of Participants
Phase 1: NHL: Cohort A: DL 3 (3x10^8 CAR+ T Cells)	Dose Escalation Phase 1: Percentage of Participants With Objective Response Rate in B Cell ALL Population	85.7 Percentage of Participants

Source: ClinicalTrials.gov · Data processed: May 7, 2026

A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

Conditions

Keywords

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Dose Escalation Phase 1: Number of Participants With Dose-limiting Toxicities (DLT) in NHL and B Cell ALL Population

Dose Expansion Phase 1 and Phase 2: Percentage of Participants With Objective Response Rate in NHL Population

Dose Escalation and Expansion: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in NHL Population

Dose Escalation and Expansion: Number of Participants With Clinically Significant Laboratory Abnormalities in NHL and B Cell ALL Population

Dose Escalation and Expansion: Number of Participants With Serious Adverse Events (SAEs) in NHL and B Cell ALL Population

Dose Escalation and Expansion: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in NHL and B Cell ALL Population

Dose Escalation and Expansion Phase 1: Duration of Response in NHL Population

Dose Escalation and Expansion Phase 1: Mean Concentration of CTX110 in Blood Over Time Following the First CTX110 Infusion in B Cell ALL Population

Dose Escalation and Expansion Phase 1: Median Overall Survival (OS) in NHL Population

Dose Escalation and Expansion Phase 1: Progression Free Survival (PFS) in NHL Population

Dose Escalation Phase 1: Percentage of Participants With Objective Response Rate in B Cell ALL Population